NCT00611247View on ClinicalTrials.gov

Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions

Leukemia, Myeloid

Interventions

DRUG

Temozolomide

"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

Bruno C. Medeiros

OTHER